CL2010000899A1 -
N1-benzyl-n8-hydroxy octanediamide; pharmaceutical composition comprising said compound; pharmaceutical combination comprising said compound; and its use in the treatment of tumors (divisional application 1247-04).
- Google Patents
N1-benzyl-n8-hydroxy octanediamide; pharmaceutical composition comprising said compound; pharmaceutical combination comprising said compound; and its use in the treatment of tumors (divisional application 1247-04).
Sloan Kettering Institute For Cancer Research And The Trustees Of Columbia Univ In The City Of New Y
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute For Cancer Research And The Trustees Of Columbia Univ In The City Of New YfiledCriticalSloan Kettering Institute For Cancer Research And The Trustees Of Columbia Univ In The City Of New Y
Priority to CL2010000899ApriorityCriticalpatent/CL2010000899A1/en
Publication of CL2010000899A1publicationCriticalpatent/CL2010000899A1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Compuesto n-bencil-n-hidroxioctanodiamida; composición y combinación farmacéutica; y su uso en el tratamiento de tumores.(divisional solicitud n 1247-04).N-Benzyl-n-hydroxyoctanediamide compound; pharmaceutical composition and combination; and its use in the treatment of tumors (divisional application n 1247-04).
CL2010000899A2010-08-232010-08-23
N1-benzyl-n8-hydroxy octanediamide; pharmaceutical composition comprising said compound; pharmaceutical combination comprising said compound; and its use in the treatment of tumors (divisional application 1247-04).
CL2010000899A1
(en)
N1-benzyl-n8-hydroxy octanediamide; pharmaceutical composition comprising said compound; pharmaceutical combination comprising said compound; and its use in the treatment of tumors (divisional application 1247-04).
N1-benzyl-n8-hydroxy octanediamide; pharmaceutical composition comprising said compound; pharmaceutical combination comprising said compound; and its use in the treatment of tumors (divisional application 1247-04).
N1-benzyl-n8-hydroxy octanediamide; pharmaceutical composition comprising said compound; pharmaceutical combination comprising said compound; and its use in the treatment of tumors (divisional application 1247-04).
Use of specific sgc stimulating and / or activating compounds; pharmaceutical formulation comprising said compounds; kit comprising the compounds, and use for the prevention and / or treatment of systematic sclerosis.
Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
Compounds derived from substituted pyrrolidine-2-carboxamides; mdm2-p53 interaction inhibitors; pharmaceutical composition; and its use for the treatment of cancer, particularly solid tumors.
Compounds derived from substituted phenylamino-benzene; Preparation method; pharmaceutical composition; farm kit; and use of said compounds in the treatment of cancer.
Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
Compounds derived from carbocyclyl / heterocyclyl-pyridin-2-yl-urea, bacterial topoisomerase iv inhibitors; pharmaceutical composition; and its use for the treatment of bacterial infections
Insulin conjugated compound; preparation procedure; pharmaceutical composition comprising it; pharmaceutical combination; pharmaceutical kit; use in the treatment of insulin-mediated disorders.
Macrocyclic aminoindole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.
Boronic acid derived compounds, proteasome inhibitors; pharmaceutical composition comprising said compound; and use of the compound for the treatment of cancer.
Pharmaceutical combination comprising compounds derived from substituted 2,3-dihydroimidazo [1,2-c] quinazoline, compounds derived from n- (2-arylamino) arylsulfonamide and optionally other additional pharmaceutical agents; pharmaceutical kit; treatment method; and its use for the treatment or prophylaxis of cancer.
Compounds derived from phenylamino-isonicotinamide; mek inhibitors; Pharmaceutical composition and use for the treatment of hyperproliferative diseases such as cancer and inflammation.
Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.